University of PittsburghUniversity of Pittsburgh
Startups
TechnologiesStartupsExpress LicensesCollectionsChat with AI
Sign in
University of Pittsburgh

Ocugenix Corp.

OverviewRequest InfoMore Like ThisExpress Licenses

Sector

Therapeutics

Therapeutic Areas

Ophthalmology

Therapeutic Indications

Diabetic retinopathyDry eye syndrome

Funding Stage

Seed

Founders

Sean McDonaldCecelia YatesAlan WellsIan Conner

Website

https://ocugenix.com/

Ocugenix is developing treatments for eye diseases involving abnormal blood-vessel growth, inflammation and fibrosis. Built on University of Pittsburgh wound-healing research, its approach activates CXCR3 signaling to address these connected processes. Programs include wet age-related macular degeneration, geographic atrophy, proliferative diabetic retinopathy and dry eye disease. [1]

Founded by Sean McDonald, Alan Wells, Cecelia Yates and Ian Conner, Ocugenix has advanced its investigational programs through early clinical studies, including Phase IIa work, while preparing its dry-eye program for clinical development. [2] [3] [4]

Discover More with AI